Lanadelumab (Takhzyro®) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/03/2019|
|Rapid review completed||23/05/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lanadelumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||28/05/2019|
|Pre-submission consultation with Applicant||20/06/2019|
|Submission received from Applicant||04/10/2019|
|Preliminary review sent to Applicant||14/02/2020|
|NCPE assessment re-commenced||13/03/2020|
|Factual accuracy check sent to Applicant||22/05/2020|
|NCPE assessment re-commenced||03/06/2020|
|NCPE assessment complete||26/06/2020|
|Current status||The NCPE recommends that lanadelumab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.